Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026. The approval adds tumor-based HRD/BRCA testing access beyond prior breast and ovarian coverage under Japan's NHI.
This expands testing options for patients with metastatic castration-resistant prostate cancer and may increase identification of PARP inhibitor candidates in Japan.
Positive
- Regulatory approval from MHLW for MyChoice in prostate cancer
- Expanded reimbursement scope beyond breast and ovarian under Japan NHI
- Increased testing options for metastatic castration-resistant prostate cancer patients
- Tumor-based HRD/BRCA testing now available in addition to germline testing
Negative
- Unspecified incremental patient volume — approval does not provide concrete testing uptake figures
- No financial guidance included to quantify near-term revenue impact from the approval
News Market Reaction – MYGN
In the Apr 14 session, MYGN gained 6.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.4% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Conference data presentations | Positive | -6.9% | Announced four ovarian cancer abstracts and SGO presence highlighting MRD and registry data. |
| Mar 17 | FDA CDx approval | Positive | -2.9% | Received FDA approval of MyChoice CDx as Zejula companion diagnostic for ovarian cancer. |
| Mar 02 | Product launch | Positive | +5.6% | Commercially launched Precise MRD ctDNA test with select community oncologists for breast cancer. |
| Feb 24 | Conference abstracts | Positive | +1.1% | Highlighted six ASCO‑GU abstracts on Precise MRD, Prolaris, and MyRisk performance data. |
| Feb 23 | Earnings and guidance | Positive | +1.1% | Reported Q4 and 2025 results, reiterated 2026 revenue and margin guidance and growth drivers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory news has produced mixed reactions, with some sell-offs on approvals/data and modest gains around commercial launches and earnings.
Over the past few months, Myriad reported several oncology-focused milestones. On Feb 23, 2026, it posted Q4 2025 revenue of $209.8M and full‑year revenue of $824.5M, down 2% year over year, while reiterating 2026 guidance. Subsequent news centered on cancer diagnostics: six abstracts at ASCO‑GU, the commercial launch of Precise MRD on Mar 2, FDA approval of MyChoice CDx for Zejula on Mar 17, and SGO presentations announced on Apr 9. The new Japan MyChoice prostate indication extends this oncology testing footprint geographically and by tumor type.
Key Terms
companion diagnostic medical
homologous recombination deficiency medical
BRCA1/2 medical
National Health Insurance (NHI) regulatory
metastatic castration-resistant medical
PARP inhibitors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers.
“Expanding the MyChoice test into prostate cancer marks an important milestone for Myriad Genetics in Japan,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. “Previously, MyChoice testing was only reimbursed under Japan’s National Health Insurance (NHI) for breast and ovarian cancer patients, so this new approval broadens access to critical genomic insights that help clinicians make informed treatment decisions for their patients. This also reflects Myriad’s continued focus on adding high value precision medicine tests to its Cancer Care Continuum portfolio.”
According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress to metastatic castration-resistant (mCRP).
“The reimbursement approval of MyChoice for prostate cancer provides a new testing option for patients with castration-resistant prostate cancer. In addition to the previously available germline BRCA1/2 testing, the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors,” said Dr. Hiroji Uemura, Project Professor, Department of Urological Oncology, Yokohama City University Graduate School of Medicine.
About the MyChoice Test
The MyChoice Test offers comprehensive homologous recombination deficiency (HRD) testing enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice tests comprise tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). The test is offered for breast, ovarian, and prostate cancer indications in Japan. For more information about Myriad Genetics in Japan, visit myriadgenetics.jp.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
